Table 3.

Diarylureas as antiviral and antimalarial agents.

Structure	Compd		Ref
Antiviral agents Inhibitors of Zika virus infection
	ASN 07115851	IC50 = 160.3 nM (by viral plaque assay and A549 human lung carcinoma cell line)	[73]
	ASN 07115873	IC50 = 189.2 pM (by viral plaque assay and A549 human lung carcinoma cell line)	[73]
	ASN 07115881	IC50 = 317.7 pM (by viral plaque assay and A549 human lung carcinoma cell line)	[73]
	ASN 07115927	IC50 = 26.9 nM (by viral plaque assay and A549 human lung carcinoma cell line)	[73]
	25	IC50 = 85.1 pM (by viral plaque assay and A549 human lung carcinoma cell line)	[74]
DENV
	26	IC50 = 91 µM (DENV N7-MTase assay) IC50 = 51 µM (WNV 2′-O-MTase assay)	[75]
	27	IC50 = 110 µM (DENV N7-MTase assay) IC50 = 71 µM (WNV 2′-O-MTase assay)	[75]
Antimalarial agents
	MMV665852	EC50 = 1160 nM (P. falciparum)	[47]
	WR268961	IC50 = 0.03‒0.16 µg/mL (P. falciparum W2 and D6)	[76]
	PQ401	EC50 = 0.053 μM (P. falciparum 3D7 and K1)	[20]
	28	EC50 = 0.32 μM (P. falciparum 3D7)	[20]
	29	EC50 = 0.031 μM (P. falciparum 3D7) EC50 = 0.11 μM (P. falciparum K1)	[20]
	30	EC50 = 0.016 μM) (P. falciparum 3D7) EC50 = 0.079 μM (P. falciparum K1)	[20]
	31	EC50 = 0.037 µM (P. falciparum 3D7) EC50 = 0.055 µM (P. falciparum Dd2)	[77]